Regeneron Pharmaceuticals (REGN) Interest & Investment Income (2009 - 2026)

Regeneron Pharmaceuticals' Interest & Investment Income history runs 18 years deep, the most recent figure standing at -$65.8 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 272.7% year-over-year to -$65.8 million in Q1 2026; TTM through Mar 2026 was -$20.9 million, a 119.32% decrease from a year earlier, with the FY2025 full-year figure at $83.0 million, up 12.77% from the prior year.
• Interest & Investment Income eased to -$65.8 million in Q1 2026 per REGN's latest filing, from $7.1 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $128.2 million in Q3 2024 and bottomed at -$144.9 million in Q1 2022.
• The 5-year median for Interest & Investment Income is $7.9 million (2024), against an average of $2.1 million.
• Across the five-year window, Interest & Investment Income tumbled 6612.5% in 2022 and jumped 988.57% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $36.3 million in 2022, then jumped by 162.81% to $95.4 million in 2023, then tumbled by 169.18% to -$66.0 million in 2024, then jumped by 110.76% to $7.1 million in 2025, then tumbled by 1026.76% to -$65.8 million in 2026.
• Per Business Quant, the three latest REGN Interest & Investment Income figures stand at -$65.8 million (Q1 2026), $7.1 million (Q4 2025), and $15.7 million (Q3 2025).